Immunovant develops autoimmune antibody drugs.
Immunovant, Inc. (IMVT) is expected to report earnings on Monday, November 9, 2026, after the close. Estimated release time 07:14 ET. Consensus EPS estimate is $-0.73.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-06 | FY2026 Q2 | $-0.63 | $-0.75 | -19.3% | $7.09M |
| 2026-05-20 | FY2026 Q1 | $-0.59 | $-0.73 | -23.3% | $0 |
| 2025-11-10 | FY2025 Q3 | $-0.72 | $-0.73 | -1.4% | $0 |
| 2025-08-11 | FY2025 Q2 | $-0.69 | $-0.71 | -2.9% | $0 |
| 2025-05-29 | FY2025 Q1 | $-0.71 | $-0.64 | +10.3% | $0 |
| 2025-02-06 | FY2024 Q4 | $-0.73 | $-0.76 | -4.1% | $0 |
| 2024-11-07 | FY2024 Q3 | $-0.61 | $-0.74 | -21.3% | $0 |
| 2024-08-06 | FY2024 Q2 | $-0.53 | $-0.60 | -13.2% | $0 |
IMVT has beaten consensus EPS in 1 of its last 8 reported quarters.
IMVT reported Aug 6. The highlights: EPS of -$0.75 — a sharp miss vs the -$0.63 estimate (-19%); revenue of $7M — in line with the $7M consensus.
See IMVT on the live calendar →